Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever
Article first published online: 16 OCT 2002
Copyright © 2002 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 46, Issue 10, pages 2785–2793, October 2002
How to Cite
Notarnicola, C., Didelot, M.-N., Koné-Paut, I., Seguret, F., Demaille, J. and Touitou, I. (2002), Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever. Arthritis & Rheumatism, 46: 2785–2793. doi: 10.1002/art.10575
- Issue published online: 16 OCT 2002
- Article first published online: 16 OCT 2002
- Manuscript Accepted: 27 JUN 2002
- Manuscript Received: 22 OCT 2001
- Centre Hospitalier de Montpellier
- Fondation pour la Recherche Médicale
Familial Mediterranean fever (FMF) is the most common inherited periodic syndrome. The disease phenotype and the almost exclusive expression of the causative gene, MEFV, in leukocytes suggest that this gene plays an important role in the inflammatory cascade. Since most of the known mutations are conservative, we sought to determine how minor DNA defects can give rise to the dramatic phenotypic features seen in FMF.
To address whether the molecular basis of the phenotype–genotype correlation could be related to altered MEFV messenger RNA (mRNA) expression, we quantified the relative abundance of MEFV transcripts in peripheral blood leukocytes from patients with FMF, healthy carriers of a single MEFV mutation, and healthy control subjects.
We found significantly lower expression of MEFV mRNA in genetically ascertained FMF patients than in healthy controls (0.7 versus 1.1; P = 0.00001). In healthy carriers, the mRNA levels were intermediate, suggesting a true dose-response relationship between the number of mutations and the abundance of MEFV transcripts. The difference between healthy controls and healthy carriers was significant (1.1 versus 0.8; P = 0.008), demonstrating that the decrease in mRNA expression is related to a molecular defect independent of FMF symptoms. MEFV mRNA expression was also found to be a function of the type of mutations. The lowest MEFV levels were found in healthy carriers and patients with M694V. Moreover, we observed an inverse correlation with the clinical severity score (r = −0.6, P = 0.04 and r = −0.6, P = 0.004 in patients with 1 and 2 M694V mutations, respectively).
Our results demonstrate that MEFV message levels are related to both the genotype and the phenotype, and suggest that the pathophysiology of FMF relies on a quantitative defect of MEFV mRNA expression.